| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
IMNM
Immunome
|
Sep 30, 2026 | BUY |
Strong Buy
+57.7% avg upside
18 analysts
|
$40.00
91.35% Upside
|
· | · |
|
ADAG
Adagene
|
Sep 29, 2026 | BUY |
Strong Buy
+160.8% avg upside
8 analysts
|
$8.00
180.65% Upside
|
· | · |
|
RVMD
Revolution Medicines
|
Sep 28, 2026 | BUY |
Strong Buy
-0.2% avg upside
34 analysts
|
$315.00
52.37% Upside
|
+2.4% | · |
|
ZYME
Zymeworks
|
Sep 28, 2026 | BUY |
Strong Buy
+32.1% avg upside
26 analysts
|
$34.00
35.21% Upside
|
-2.3% | · |
|
RCUS
Arcus Biosciences
|
Sep 27, 2026 | BUY |
Strong Buy
+44.9% avg upside
21 analysts
|
$46.00
88.22% Upside
|
+0.0% | · |
|
IDYA
IDEAYA Biosciences
|
Sep 27, 2026 | BUY |
Strong Buy
+28.7% avg upside
29 analysts
|
$58.00
55.30% Upside
|
· | · |
|
CMPX
Compass Therapeutics
|
Sep 22, 2026 | HOLD |
Strong Buy
+759.8% avg upside
20 analysts
|
— | -11.3% | · |
|
BLSM
BlossomHill Therapeutics, Inc.
|
Sep 15, 2026 | BUY |
Strong Buy
+83.0% avg upside
5 analysts
|
$32.00
62.54% Upside
|
-15.9% | · |
|
MOLN
Molecular Partners
|
Aug 25, 2026 | BUY |
Strong Buy
+148.4% avg upside
7 analysts
|
$12.00
198.06% Upside
|
-11.9% | · |
|
PBLS
Parabilis Medicines, Inc.
|
Aug 13, 2026 | BUY |
Strong Buy
+41.3% avg upside
6 analysts
|
$42.00
38.73% Upside
|
-9.5% | · |
|
KURA
Kura Oncology
|
Aug 13, 2026 | BUY |
Strong Buy
+145.9% avg upside
27 analysts
|
$28.00
162.85% Upside
|
+5.5% | · |
|
STRO
Sutro Biopharma
|
Aug 12, 2026 | BUY |
Strong Buy
+170.9% avg upside
22 analysts
|
$54.00
251.79% Upside
|
-24.4% | · |
|
TARA
Protara Therapeutics
|
Aug 11, 2026 | BUY |
Strong Buy
+1806.4% avg upside
21 analysts
|
$20.00
640.67% Upside
|
-30.9% | · |
|
CNTX
Context Therapeutics
|
Aug 08, 2026 | HOLD |
Strong Buy
+1599.0% avg upside
12 analysts
|
$2.00
545.71% Upside
|
-23.4% | · |
|
CBIO
Crescent Biopharma
|
Jul 30, 2026 | BUY |
Strong Buy
+55.6% avg upside
17 analysts
|
$28.00
95.55% Upside
|
-6.9% | · |
|
GYRE
Gyre Therapeutics
|
Jun 18, 2025 | BUY |
Strong Buy
+191.7% avg upside
15 analysts
|
$22.00
209.50% Upside
|
-25.0% | · |
|
TNGX
Tango Therapeutics
|
May 24, 2024 | BUY |
Strong Buy
+66.6% avg upside
15 analysts
|
$14.00
39.85% Downside
|
-73.4% | · |
|
MGNX
MacroGenics
|
Jan 02, 2024 | BUY |
Buy
+396.0% avg upside
25 analysts
|
$20.00
458.73% Upside
|
-67.6% | · |
|
COGT
Cogent Biosciences
|
Jun 13, 2023 | BUY |
Strong Buy
+24.4% avg upside
26 analysts
|
$26.00
16.25% Downside
|
-30.1% | · |
|
XNCR
Xencor
|
May 09, 2023 | BUY |
Strong Buy
+43.6% avg upside
27 analysts
|
$39.00
57.02% Upside
|
-12.3% | · |
|
TRAW
Traws Pharma
|
Mar 17, 2023 | BUY |
Buy
+5442.0% avg upside
10 analysts
|
$5.00
779.55% Upside
|
+3.8% | · |
|
NGNE
Neurogene
|
Jan 03, 2023 | HOLD |
Strong Buy
+89.0% avg upside
23 analysts
|
— | +93.8% | · |
|
PMVP
PMV Pharmaceuticals
|
Jan 03, 2023 | BUY |
Strong Buy
+680.6% avg upside
13 analysts
|
$20.00
1017.39% Upside
|
-65.1% | · |
|
TSE:MDNA
Medicenna Therapeutics Corp
|
Nov 29, 2022 | BUY |
Strong Buy
+1167.7% avg upside
9 analysts
|
$2.00
419.50% Upside
|
-23.0% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.